Voyager Therapeutics, Inc. (NASDAQ:VYGR) Given Consensus Recommendation of “Buy” by Brokerages

Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) have been assigned an average recommendation of “Buy” from the nine research firms that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation, seven have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $17.00.

VYGR has been the topic of several research reports. Leerink Partnrs raised Voyager Therapeutics to a “strong-buy” rating in a research report on Wednesday, October 16th. StockNews.com upgraded Voyager Therapeutics from a “hold” rating to a “buy” rating in a report on Monday. Canaccord Genuity Group reiterated a “buy” rating and issued a $14.00 target price on shares of Voyager Therapeutics in a research note on Thursday, November 14th. HC Wainwright restated a “buy” rating and set a $30.00 price target on shares of Voyager Therapeutics in a research note on Thursday, November 14th. Finally, Leerink Partners assumed coverage on shares of Voyager Therapeutics in a report on Wednesday, October 16th. They set an “outperform” rating and a $15.00 price target on the stock.

Insiders Place Their Bets

In related news, insider Sandell Jacquelyn Fahey sold 5,999 shares of Voyager Therapeutics stock in a transaction that occurred on Wednesday, October 2nd. The stock was sold at an average price of $5.82, for a total value of $34,914.18. Following the sale, the insider now owns 86,001 shares of the company’s stock, valued at approximately $500,525.82. This trade represents a 6.52 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 4.53% of the company’s stock.

Hedge Funds Weigh In On Voyager Therapeutics

A number of large investors have recently modified their holdings of VYGR. Ameritas Investment Partners Inc. boosted its stake in shares of Voyager Therapeutics by 49.6% during the 1st quarter. Ameritas Investment Partners Inc. now owns 3,923 shares of the company’s stock worth $37,000 after acquiring an additional 1,300 shares during the period. Plato Investment Management Ltd acquired a new stake in shares of Voyager Therapeutics during the 1st quarter worth about $38,000. China Universal Asset Management Co. Ltd. raised its holdings in Voyager Therapeutics by 64.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,489 shares of the company’s stock valued at $61,000 after acquiring an additional 4,098 shares during the period. Intech Investment Management LLC acquired a new stake in Voyager Therapeutics during the third quarter worth approximately $74,000. Finally, SG Americas Securities LLC bought a new stake in shares of Voyager Therapeutics during the second quarter worth approximately $85,000. 48.03% of the stock is currently owned by institutional investors and hedge funds.

Voyager Therapeutics Price Performance

NASDAQ VYGR opened at $5.43 on Friday. The company has a market capitalization of $296.64 million, a P/E ratio of 7.65 and a beta of 0.89. Voyager Therapeutics has a 12 month low of $5.19 and a 12 month high of $11.72. The company’s 50 day simple moving average is $6.57 and its 200 day simple moving average is $7.43.

Voyager Therapeutics (NASDAQ:VYGR) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.29. Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. The firm had revenue of $24.63 million for the quarter, compared to analysts’ expectations of $12.63 million. During the same quarter last year, the business posted ($0.59) EPS. On average, analysts anticipate that Voyager Therapeutics will post -1.03 earnings per share for the current year.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.